Full Press Release Details
Therapeutics, Inc. Renews Shareholder Rights Plan
BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ: ANIK)
announced today that its Board of Directors has renewed its Shareholder
Rights Plan. The renewed plan is similar to the original plan that had
been in existence for 10 years and is due to expire soon. Shareholder
rights plans are designed to strengthen the ability of a board of
directors to protect a company's stockholders against abusive or
coercive takeover tactics that are not in the best interests of the
company and its stockholders.
Details of the plan can be found in Anika's Form 8-K, which will be
filed shortly with the Securities and Exchange Commission.
About Anika Therapeutics, Inc.
Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
manufactures and commercializes therapeutic products for tissue
protection, healing and repair. These products are based on hyaluronic
acid (HA), a naturally occurring, biocompatible polymer found throughout
the body. Anika's products include ORTHOVISC , a
treatment for osteoarthritis of the knee available internationally and
marketed in the U.S. by DePuy Mitek; HYVISC , a
treatment for equine osteoarthritis marketed in the U.S. by Boehringer
Ingelheim Vetmedica, Inc.; the ELEVESS family of
aesthetic dermatology products for facial wrinkles, scar remediation and
lip augmentation; AMVISC , AMVISC Plus,
STAARVISC -II and Shellgel injectable viscoelastic HA products for
ophthalmic surgery; INCERT , an HA-based anti-adhesive
for surgical applications; ORTHOVISC Mini a
treatment for osteoarthritis targeting small joints and available in
Europe, MONOVISC a single-injection osteoarthritis
product based on our proprietary cross-linking technology and scheduled
to launch in Europe mid year 2008, and next generation
products for joint health and aesthetic dermatology based on the
Company's proprietary, chemically modified HA.
Anika Therapeutics, Inc.
Charles H. Sherwood, Ph.D.,
Kevin W. Quinlan, 781-457-9000